FrancophonIA/ELRC3.0 huggingface dataset:
English: Repeated-dose toxicity studies in rats of up to 6 months in duration and in dogs up to 9 months in duration revealed the gastrointestinal system to be the primary target organ of toxicity of bosutinib.
Croatian: Ispitivanja toksičnosti ponovljenih doza u štakora u trajanju do 6 mjeseci i u pasa u trajanju do 9 mjeseci pokazala su da je primarni ciljni organ toksičnosti bosutiniba gastrointestinalni sustav.
English: If a dose is missed by more than 12 hours, the patient should not be given an additional dose.
Croatian: Ako se propusti doza za više od 12 sati, bolesnik ne smije primiti dodatnu dozu.
English: Women of childbearing potential/Contraception
Croatian: Žene reproduktivne dobi/kontracepcija
English: Note: Baseline mutations were identified before the patient's first dose of study drug.
Croatian: Napomena: mutacije na početku identificirane su prije bolesnikove prve doze ispitivanog lijeka.
English: Bosutinib can induce severe skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Croatian: Bosutinib može izazvati teške kožne reakcije poput Stevens-Johnsonova sindroma i toksične epidermalne nekrolize.
English: Doses greater than 600 mg/day have not been studied and, therefore, should not be given.
Croatian: Doze veće od 600 mg/dan još nisu ispitivane i stoga se ne smiju davati.
English: Bosutinib has no or negligible influence on the ability to drive and use machines.
Croatian: Bosutinib ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE14.
Croatian: Farmakoterapijska skupina: antineoplastici, inhibitori protein-kinaze, ATK oznaka: L01XE14.
English: In clinical trials for both indications, treatment with bosutinib continued until disease progression or intolerance to therapy.
Croatian: U kliničkim ispitivanjima za obje indikacije liječenje bosutinibom nastavljeno je do progresije bolesti ili intolerancije terapije.
English: Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver infection).
Croatian: Ponovna aktivacija hepatitisa B: Ponovna pojava (ponovna aktivacija) infekcije virusom hepatitisa B ako ste u prošlosti imali hepatitis B (infekciju jetre).
English: This medicinal product has been authorised under a so-called “conditional approval” scheme.
Croatian: Ovaj lijek je odobren po shemi takozvanog “uvjetnog odobrenja“.
English: The safety and efficacy of bosutinib in children and adolescents less than 18 years of age have not been established.
Croatian: Sigurnost i djelotvornost bosutiniba u djece i adolescenata mlađe od 18 godina još nisu ustanovljene.
English: Includes patients (N) who attained or maintained CHR for CP patients and OHR for AP and BP patients.
Croatian: Uključuje bolesnike (N) koji su dostigli ili održali CHR za bolesnike u CP-u i OHR za bolesnike u AP-u i BP-u.
English: - if you have been told that you have problems with your kidneys.
Croatian: - ako Vam je rečeno da imate problema s bubrezima.
English: Population pharmacokinetic analyses in patients with Ph+ leukaemia or malignant solid tumour indicate that there are no clinically relevant effects of age, gender, body weight, race.
Croatian: Farmakokinetičke analize populacije u bolesnika s Ph+ leukemijom ili malignim solidnim tumorom upućuju da nema klinički značajnih učinaka dobi, spola, tjelesne težine i rase.
English: If dose is missed by less than 12 hours, take your recommended dose.
Croatian: Ako je od propuštene doze prošlo manje od 12 sati, uzmite svoju preporučenu dozu.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Bosulif in one or more subsets of the paediatric population in CML (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja lijeka Bosulif u jednoj ili više podskupina pedijatrijske populacije s KML-om (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: If blood counts remain low for > 2 weeks, upon recovery reduce dose by 100 mg and resume treatment.
Croatian: Ako vrijednosti krvne slike ostaju niske > 2 tjedna, nakon oporavka smanjiti dozu za 100 mg i nastaviti liječenje.
English: If you have any questions about how Bosulif works or why this medicine has been prescribed for you, ask your doctor.
Croatian: Ako imate pitanja o djelovanju lijeka Bosulif ili o razlogu zašto Vam je lijek propisan, obratite se svom liječniku.
English: Women taking Bosulif will be advised to use effective contraception during treatment and for at least 1 month after the last dose.
Croatian: Žene koje uzimaju Bosulif će se savjetovati da koriste učinkovitu kontracepciju tijekom liječenja i do najmanje mjesec dana nakon zadnje doze.
English: If clinically appropriate, re-escalation to the dose prior to the dose reduction taken once daily should be considered (see section 4.4).
Croatian: Ako je klinički primjereno, treba razmotriti ponovno postupno povećanje do doze koja se primjenjivala prije smanjivanja doze uzete jedanput dnevno (vidjeti dio 4.4).
English: Do not breast-feed during treatment with Bosulif as it could harm your baby.
Croatian: Nemojte dojiti za vrijeme liječenja lijekom Bosulif jer bi to moglo naškoditi Vašem djetetu.
English: What do you need to know before you take take Bosulif
Croatian: Što morate znati prije nego počnete uzimati Bosulif
English: Bosulif will only be prescribed to you by a doctor with experience in medicines to treat leukaemia.
Croatian: Bosulif će Vam propisati jedino liječnik koji ima iskustva s lijekovima za liječenje leukemije.
English: You should ask your doctor if use of your treatment for vomiting may result in a greater risk of heart arrhythmias.
Croatian: Morate pitati svog liječnika može li liječenje koje uzimate protiv povraćanja povećati opasnost od srčanih aritmija.
English: Overall haematological response (OHR)=major haematological response (complete haematological response + no evidence of leukaemia) or return to chronic phase (RCP).
Croatian: Ukupni hematološki odgovor (OHR) = veliki hematološki odgovor (potpuni hematološki odgovor i bez dokaza leukemije) ili povratak u kroničnu fazu.
English: If you accidentally take too many Bosulif tablets or a higher dose than you need, contact a doctor for advice right away.
Croatian: Ako slučajno uzmete više tableta lijeka Bosulif ili veću dozu nego što ste trebali, odmah se obratite svom liječniku za savjet.
English: Genotoxicity studies in bacterial in vitro systems and in mammalian in vitro and in vivo systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of bosutinib.
Croatian: Ispitivanja genotoksičnosti u bakterijskim in vitro sustavima te u sisavaca u in vitro i in vivo sustavima, sa i bez metaboličke aktivacije, nisu pokazala mutageni potencijal bosutiniba.
English: Bosutinib minimally inhibits platelet-derived growth factor (PDGF) receptor and c-Kit.
Croatian: Bosutinib minimalno inhibira receptor trombocitnog čimbenika rasta (engl. plateletderived growth factor, PDGF) i c-Kit.
English: Vomiting or diarrhoea may reduce the effectiveness of oral contraceptives.
Croatian: Povraćanje ili proljev mogu smanjiti učinkovitost peroralne kontracepcije.
English: Patients should be monitored and managed using standard-of-care treatment.
Croatian: Bolesnici moraju biti praćeni i zbrinuti liječenjem koje se temelji na standardnoj skrbi.
English: Dose reductions are recommended for severe or persistent neutropenia and thrombocytopenia as described in Table 1:
Croatian: Preporučuje se smanjivanje doza kod teških ili upornih neutropenija i trombocitopenija kao što je opisano u Tablici 1:
English: In vitro testing indicated that bosutinib had limited activity against the T315I or the V299L mutation.
Croatian: In vitro ispitivanje pokazalo je da je bosutinib imao ograničenu aktivnost protiv mutacije T315I ili V299L.
English: Also tell your doctor if you are losing weight or have experienced swelling of your feet, ankles, legs, hands or face.
Croatian: Također obavijestite svog liječnika ako gubite na težini ili Vam otiču stopala, gležnjevi, noge, ruke ili lice.
English: Bosutinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity, and photoxicity studies.
Croatian: Bosutinib je procijenjen u ispitivanjima sigurnosne farmakologije, toksičnosti ponovljene doze, genotoksičnosti, reproduktivne toksičnosti i fototoksičnosti.
English: A proarrhythmic potential of bosutinib cannot be ruled out.
Croatian: Ne može se isključiti proaritmički potencijal bosutiniba.
English: Treatment with bosutinib is associated with elevations in serum transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]).
Croatian: Liječenje bosutinibom povezano je s porastom serumskih transaminaza (alanin aminotransferaze [ALT], aspartat aminotransferaze [AST]).
English: Based on the limited clinical information from the Phase 1/2 study, some evidence of clinical activity was observed in patients with BCR-ABL mutations (see Table 6).
Croatian: Temeljeno na ograničenim kliničkim podacima iz ispitivanja iz faze 1/2, zapaženo je nešto dokaza kliničke aktivnosti u bolesnika s mutacijama BCR-ABL-a (vidjeti Tablicu 6).
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Croatian: Unutar svake skupine učestalosti, nuspojave su navedene u padajućem nizu prema ozbiljnosti.
English: Following a single oral (10 mg/kg) administration of [
Croatian: Nakon jedne peroralne (10 mg/kg) primjene radioaktivno [
English: The median duration of therapy was 13.8 months (range: 0.03 to 123.3 months).
Croatian: Medijan trajanja terapije bio je 13,8 mjeseci (raspon: 0,03 do 123,3 mjeseca).
English: Concomitant medicinal products were given to treat diarrhoea in 662 (66%) patients.
Croatian: Istodobno su davani lijekovi za liječenje proljeva u 662 (66%) bolesnika.
English: The evaluable population includes patients who had a valid baseline disease assessment.
Croatian: Procjenjiva populacija uključuje bolesnike koji su imali važeću početnu procjenu bolesti.
English: Treatment of nausea or vomiting with such medicines together with Bosulif may result in a greater risk of dangerous heart arrhythmias.
Croatian: Liječenje mučnine ili povraćanja takvim lijekovima zajedno s lijekom Bosulif može povećati opasnost od srčanih aritmija.
English: Bosulif is not to be used during pregnancy, unless clearly necessary, because Bosulif could harm an unborn baby.
Croatian: Bosulif se ne smije primjenjivati tijekom trudnoće, osim ako je to nužno, jer može naškoditi nerođenome djetetu.
English: Foetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental transfer study in gravid Sprague-Dawley rats.
Croatian: Fetalna izloženost radioaktivnosti izvedenoj iz bosutiniba tijekom trudnoće dokazana je u ispitivanju transplacentarnog prijenosa u gravidnih Sprague-Dawley štakora.
English: If you take more Bosulif than you should
Croatian: Ako uzmete više lijeka Bosulif nego što ste trebali
English: Females were observed with increased embryonic resorptions, and decreases in implantations and viable embryos.
Croatian: U ženki su zabilježeni porast embrionalnih resorpcija, smanjenja implantacija i vijabilnih embrija.
English: Effects of other medicinal products on bosutinib
Croatian: Učinci drugih lijekova na bosutinib
English: Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
Croatian: Kao zamjenu IPP-ma treba uzeti u obzir antacide kratkog djelovanja, a vremena primjene bosutiniba i antacida moraju biti odvojena (tj. bosutinib se uzima ujutro, a antacidi navečer) kadgod je to moguće.
English: Very common Lipase increased (including Hyperlipasaemia) Common
Croatian: Porast lipaze (uključujući hiperlipazemiju)
English: Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
Croatian: Liječenje mora započeti liječnik iskusan u dijagnosticiranju i liječenju bolesnika s KML-om.
English: It is unknown whether bosutinib and its metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se bosutinib i njegovi metaboliti u majčino mlijeko u ljudi.
English: In these situations an individual benefit-risk assessment is mandatory and patients should be monitored for occurrence of QTc prolongation.
Croatian: U tim je situacijama obavezna individualna procjena omjera koristi i rizika, a bolesnike se mora pratiti kako bi se uočila pojava produljenog QTc intervala.
English: Transaminase elevations generally occurred early in the course of treatment (of the patients who experienced transaminase elevations of any grade, > 80% experienced their first event within the first 3 months).
Croatian: Porast transaminaza većinom se javljao na početku liječenja (od bolesnika koji su imali porast transaminaza bilo kojeg stupnja, > 80% imalo je prvi događaj unutar prvih 3 mjeseca).
English: Proton pump inhibitors (PPIs)
Croatian: Inhibitori protonske pumpe (IPP)
English: - if you suffer from bleeding problems.
Croatian: - ako imate problema s krvarenjem.
English: Heart problems.
Croatian: Problemi sa srcem.
English: However, if a patient taking bosutinib experiences dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely, the patient should refrain from these activities for as long as the undesirable effects persist.
Croatian: Međutim, ako se u bolesnika koji uzima bosutinib pojave omaglica, umor, oštećenje vida ili druge nuspojave s potencijalnim utjecajem na sposobnost sigurnog upravljanja vozilima ili rada sa strojevima, bolesnik se mora suzdržati od tih aktivnosti dokle god traju nuspojave.
English: Dose adjustments for renal impairment were based on the results of this study, and the known linear pharmacokinetics of bosutinib in the dose range of 200 to 600 mg.
Croatian: Prilagodbe doze za oštećenje bubrega temelje se na rezultatima ovog ispitivanja te poznatoj linearnoj farmakokinetici bosutiniba u rasponu doze od 200 do 600 mg.
English: Erythema multiforme
Croatian: Multiformni eritem
English: The data from this study indicate that bosutinib does not prolong the QTc in healthy subjects at the dose of 500 mg daily with food, and under conditions that give rise to supratherapeutic plasma concentrations.
Croatian: Podaci iz navedenog ispitivanja upućuju da bosutinib ne produljuje QTc u zdravih ispitanika pri dozi od 500 mg dnevno s hranom i u uvjetima koji uzrokuju supraterapijske koncentracije u plazmi.
English: Patients who take an overdose of bosutinib should be observed and given appropriate supportive treatment.
Croatian: Bolesnike koji su predozirani bosutinibom mora se promatrati i pružiti im odgovarajuće potporno liječenje.
English: This allowed measurable concentrations of radioactivity to appear in the plasma of nursing pups.
Croatian: To je omogućilo pojavu mjerljivih koncentracija radioaktivnosti u plazmi okota tijekom dojenja.
English: Hepatic impairment (see sections 5.1 and 5.2).
Croatian: Oštećenje funkcije jetre (vidjeti dijelove 5.1 i 5.2).
English: This being a conditional marketing authorisation and pursuant to Article 14(7) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:
Croatian: Uredbe (EZ) br. 726/2004, nositelj odobrenja dužan je unutar navedenog vremenskog roka provesti sljedeće mjere:
English: The systemic exposure of N-desmethylated metabolite was 25% of the parent compound, while the oxydechlorinated metabolite was 19% of the parent compound.
Croatian: Sistemska izloženost Ndesmetiliranog metabolita bila je 25% ishodišnog lijeka, dok je oksidekloriniran metabolit bio 19% ishodišnog lijeka.
English: Grapefruit products, including grapefruit juice and other foods that are known to inhibit CYP3A should be avoided (see section 4.5).
Croatian: Moraju se izbjegavati proizvodi od grejpa, uključujući sok od grejpa i drugu hranu za koju se zna da inhibira CYP3A (vidjeti dio 4.5).
English: The study results indicate that bosutinib does not exhibit clinically relevant P-gp inhibitory effects.
Croatian: Rezultati ispitivanja upućuju na to da bosutinib ne pokazuje klinički značajne učinke inhibicije P-gp-a.
English: A delayed increase in heart rate was observed.
Croatian: Opažen je odgođeni porast srčane frekvencije.
English: There is a risk that treatment with Bosulif will lead to decreased fertility and you may wish to seek advice about sperm storage before the treatment starts.
Croatian: Postoji rizik da liječenje lijekom Bosulif može uzrokovati smanjenu plodnost i možda ćete htjeti potražiti savjet oko pohranjivanja sperme prijepočetka liječenja.
English: Other efficacy endpoints include transformation to AP/BP, progression free survival and OS for all cohorts.
Croatian: Druge mjere ishoda djelotvornosti uključuju transformaciju u AP/BP, preživljenje bez progresije (engl. progression free survival, PFS) i ukupno preživljenje u svim kohortama.
English: The recommended dose is 500 mg once daily for patients whose previous medicines to treat CML have either not worked or are not suitable.
Croatian: Preporučena doza je 500 mg jedanput dnevno u bolesnika u kojih prethodni lijekovi za liječenje KMLa nisu bili učinkoviti ili nisu prikladni.
English: Four patients (0.3%) experienced QTcF interval prolongation (greater than 500 ms).
Croatian: Četiri bolesnika (0,3%) imala su produljenje QTcF intervala (više od 500 ms).
English: White opaque 3-ply PVC/Polychlorotrifluoroethene/PVC blister sealed with push-through foil backing containing either 14 or 15 tablets.
Croatian: Bijeli, neprozirni, troslojni PVC/poliklorotrifluoroeten/PVC blister zatvoren folijom kroz koju se protisnu tablete, koji sadrži 14 ili 15 tableta.
English: Cytogenetic Response criteria: Major Cytogenetic Response included Complete [0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridisation (FISH)] or partial (1%-35%) cytogenetic responses.
Croatian: Kriteriji citogenetskog odgovora: veliki citogenetski odgovor uključivao je potpune [0% Ph+ metafaza u koštanoj srži ili < 1% pozitivnih stanica u fluorescentnoj in situ hibridizaciji (FISH)] ili parcijalne (1%-35%) citogenetske odgovore.
English: - if you have, or have had in the past, liver problems.
Croatian: - ako imate, ili ste u prošlosti imali probleme s jetrom.
English: Safety pharmacology
Croatian: Sigurnosna farmakologija
English: Severe skin reactions.
Croatian: Teške kožne reakcije.
English: Bosutinib has demonstrated the ability to absorb light in the UV-B and UV-A range and is distributed into the skin and uveal tract of pigmented rats.
Croatian: Bosutinib je pokazao sposobnost apsorpcije svjetlosti u rasponima UV-B i UV-A te se distribuirao u kožu i srednju očnu ovojnicu pigmentiranih štakora.
English: - if you have fluid retention.
Croatian: - ako imate zadržavanje tekućine.
English: Following administration of a single dose of bosutinib (500 mg) with food in healthy subjects, the absolute bioavailability was 34%.
Croatian: Nakon primjene jedne doze bosutiniba (500 mg) s hranom u zdravih ispitanika, apsolutna bioraspoloživost je bila 34%.
English: Bosutinib is not recommended for use during pregnancy, or in women of childbearing potential not using contraception.
Croatian: Ne preporučuje se koristiti bosutinib tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
English: Paediatric population Bosulif has not yet been studied in children and adolescents less than 18 years of age.
Croatian: Pedijatrijska populacija Bosulif još nije ispitan u djece i adolescenata mlađe od 18 godina.
English: Age, gender and race
Croatian: Dob, spol i rasa
English: In addition, 5.6% of patients in the bosutinib treatment group had further dose escalations to 600 mg.
Croatian: Osim toga, u 5,6% bolesnika iz skupine liječene bosutinibom doza je dodatno postupno povećavana do 600 mg.
English: Maximal exposure Cmax increased by 28% and 34% in the moderate and severe groups, respectively.
Croatian: Maksimalna izloženost Cmax porasla je u skupinama s umjerenim i teškim oštećenjem za 28%, odnosno 34%.
English: Patients should be tested for HBV infection before initiating treatment with bosutinib.
Croatian: Bolesnike je potrebno testirati na infekciju HBV-om prije početka liječenja bosutinibom.
English: 9/L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% basophils in peripheral blood, and no extramedullary involvement.
Croatian: 9/l, odsustvo blasta ili promijelocita u perifernoj krvi, manje od 5% mijelocita + metamijelocita u koštanoj srži, manje od 20% bazofila u perifernoj krvi i odsustvo ekstramedularne zahvaćenosti.
English: Table 4 - Comparison of MMR at Months 3, 6, and 9 by treatment in the mITT population
Croatian: Tablica 4 - Usporedba značajnog molekularnog odgovora (MMR) u 3., 6. i 9. mjesecu prema liječenju u mITT populaciji
English: The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Croatian: Nositelj odobrenja obavljat će zadane farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom Planu upravljanja rizikom (RMP), koji se nalazi u Modulu 1.8.2 Odobrenja za stavljanje lijeka u promet, te svim sljedećim dogovorenim ažuriranim verzijama RMPa.
English: If bosutinib is used during pregnancy, or the patient becomes pregnant while taking bosutinib, she should be apprised of the potential hazard to the foetus.
Croatian: Ako bolesnica koristi bosutinib tijekom trudnoće, ili zatrudni za vrijeme uzimanja bosutiniba, mora biti obaviještena o potencijalnom riziku za plod.
English: Snapshot date: 02Oct2015
Croatian: Datum prikazanog stanja: 2. listopada 2015.
English: Pfizer Ελλάς Α.Ε.
Croatian: Pfizer Ελλάς A.E.
English: After a minimum of 12 months of follow-up in the mITT population, 77.6% of patients treated with bosutinib (N=241) and 72.4% of patients treated with imatinib (N=239) were still receiving first-line treatment.
Croatian: Nakon najmanje 12 mjeseci praćenja u mITT populaciji 77,6% bolesnika liječenih bosutinibom (N = 241) i 72,4% bolesnika liječenih imatinibom (N = 239) još su primali prvu liniju liječenja.
English: Blood creatinine increased, Amylase increased, Blood creatine phosphokinase increased
Croatian: Porast kreatinina u krvi, porast amilaze u krvi, porast kreatin fosfokinaze u krvi
English: Patients with serum creatinine > 1.5 × ULN were excluded from the CML studies.
Croatian: Bolesnici sa serumskim kreatininom > 1,5 × GGN bili su isključeni iz ispitivanja KML-a.
English: Effects of bosutinib on other medicinal products
Croatian: Učinci bosutiniba na druge lijekove
English: Bosulif film-coated tablets come in different strengths.
Croatian: Bosulif filmom obložene tablete isporučuju se u različitim jačinama.
English: Chest pain (including Chest discomfort), Pain
Croatian: Bol u prsištu (uključujući nelagodu u prsištu), bol
English: - This medicine does not require any special storage conditions.
Croatian: - Lijek ne zahtijeva posebne uvjete čuvanja.
English: Toxicities were characterised by an increase in liver weights in correlation with hepatocellular hypertrophy which occurred in the absence of elevated liver enzymes or microscopic signs of hepatocellular cytotoxicity, and is of unknown relevance to humans.
Croatian: Toksičnosti su bile obilježene povećanjem težine jetre u korelaciji s hepatocelularnom hipertrofijom koja se pojavila u odsustvu povišenih jetrenih enzima ili mikroskopskih znakova hepatocelularne citotoksičnosti te je važnost u ljudi nepoznata.
English: Bosutinib inhibited 16 of 18 imatinib-resistant forms of BCR-ABL expressed in murine myeloid cell lines.
Croatian: Bosutinib je inhibirao 16 od 18 oblika BCR-ABL-a rezistentnih na imatinib izraženih u mijeloidnim staničnim linijama miševa.